All Articles
PD-L1: The Story So Far

PD-L1: The Story So Far

29 September, 2017

PD-L1 has been one of the most talked about new biomarkers in the context of targeted therapy. This Ebook looks at the dynamic PD-L1 space and discusses topics such as test availability, integration alongside more established biomarkers, complementary testing and how a suboptimal PD-L1 diagnostic marketplace can lead to lost treatment opportunities.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.